Provided by Tiger Trade Technology Pte. Ltd.

Intellia Therapeutics

11.71
-0.6600-5.34%
Post-market: 11.760.0500+0.43%17:57 EDT
Volume:8.29M
Turnover:98.88M
Market Cap:1.64B
PE:-3.50
High:12.41
Open:12.08
Low:11.70
Close:12.37
52wk High:28.25
52wk Low:7.95
Shares:140.00M
Float Shares:137.56M
Volume Ratio:1.37
T/O Rate:6.02%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.3456
EPS(LYR):-3.8100
ROE:-55.44%
ROA:-30.14%
PB:2.25
PE(LYR):-3.07

Loading ...

Intellia Therapeutics Announces FDA Acceptance of Biologics License Application with Priority Review for Lonvoguran Ziclumeran (Lonvo-Z) for Hereditary Angioedema (Hae)

THOMSON REUTERS
·
Sep 08

Intellia Therapeutics, - FDA not Planning to Hold Advisory Committee for Lonvo-Z Application

THOMSON REUTERS
·
Sep 08

Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Intellia Therapeutics (NTLA) and Ultragenyx Pharmaceutical (RARE)

TIPRANKS
·
Sep 08

Intellia Therapeutics Secures Major Non-Dilutive Loan Financing

TIPRANKS
·
Sep 05

Intellia Awards 163,100 RSUs to 41 New Employees Under Inducement Plan

Reuters
·
Sep 05

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Sep 05

Intellia Therapeutics Secures $400 Million Senior Secured Term Loan Facility with OrbiMed

Reuters
·
Sep 04

Intellia Therapeutics, - Additional $100 Mln Available Subject to Mutual Agreement During Five-Year Term

THOMSON REUTERS
·
Sep 04

Intellia Therapeutics to Present at Morgan Stanley 24th Annual Global Healthcare Conference

GlobeNewswire
·
Sep 04

Cathie Wood’s ARK Investment buys 96.2K shares of Intellia Therapeutics today

TIPRANKS
·
Sep 03

Intellia Therapeutics (NTLA) Stock May Be Fully Priced Despite Its 92% Slide

Simply Wall St.
·
Aug 27

Intellia Therapeutics Price Target Maintained with a $30.00/Share by Citizens

Dow Jones
·
Aug 25

Cathie Wood’s ARK Investment buys 169K shares of Intellia Therapeutics today

TIPRANKS
·
Aug 25

Intellia CEO John M. Leonard Disposes of USD 286,764 in Common Shares

Reuters
·
Aug 25

Intellia Therapeutics: Buy Rating Reiterated as Clinical Progress and Risk Management Support Unchanged $29 Price Target

TIPRANKS
·
Aug 15

Intellia Grants Inducement RSUs for 38,200 Shares to Eight New Employees

Reuters
·
Aug 08

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Aug 08

Analysts Have Conflicting Sentiments on These Healthcare Companies: Intellia Therapeutics (NTLA), Haemonetics (HAE) and Nuvation Bio (NUVB)

TIPRANKS
·
Aug 07

CytomX Q2 Revenue Misses, Partly Hurt by Lower Research Activities in the Astellas Collaboration

Reuters
·
Aug 07

Solid Biosciences Q2 Net Loss Widens on Higher R&D Costs

Reuters
·
Aug 07